GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Mankind Pharma Ltd

Mankind Pharma Board Approves Q2 FY27 Results & Amalgamation Schemes

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 26 Oct 2026, 03:14 PM IST  ·  BSE ID: a4cf61b4-7b7e-4216-9fef-fb78806aa271
View Original BSE Filing (PDF)
💡
In Simple Terms
The company announced its latest financial results and plans to merge two of its fully-owned smaller companies into itself.
🤖 AI Summary
  • Mankind Pharma Board approved unaudited standalone financial results for Q2 FY27, with Profit for the period of Rs. 581.95 Crores.
  • The Board approved the amalgamation scheme of Prolijune Lifesciences and Pavi Buildwell, wholly-owned subsidiaries, into Mankind Pharma.
  • Appointed Date for the amalgamation of Prolijune Lifesciences and Pavi Buildwell is April 01, 2027.
  • Board noted amalgamation scheme of Upakarma Ayurveda with Mankind Consumer Products, a step-down wholly owned subsidiary.
  • Both amalgamation schemes are subject to necessary statutory and regulatory approvals.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Revenue from operations (Q2 FY27)
3,145.22 Crores
Standalone Profit for the period (Q2 FY27)
581.95 Crores
Standalone Revenue from operations (H1 FY27)
6,109.27 Crores
Standalone Profit for the period (H1 FY27)
1,140.44 Crores
🏢 How This Affects the Company
📈
Business Impact
The amalgamation schemes for wholly-owned subsidiaries aim to streamline the corporate structure, potentially leading to operational efficiencies.
💰
Financial Impact
The approved standalone profit for Q2 FY27 stands at Rs. 581.95 Crores, contributing to the company's half-yearly earnings of Rs. 1,140.44 Crores.
⚙️
Operational Impact
Consolidation of wholly-owned subsidiaries could simplify operations by integrating management and administrative functions.
⚠️
Risk Impact
The income tax proceedings against the company, as noted by auditors, present an ongoing financial risk until resolved by appellate tax authorities.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this filing.
👤
Who Is Affected
Shareholders will be indirectly affected by the financial performance of the company, with standalone profit for the period at Rs. 581.95 Crores, and by the strategic corporate restructuring of wholly-owned subsidiaries.
🔍
Management Signal
Management is signaling a focus on optimizing corporate structure and driving profitability, as evidenced by financial results and proposed subsidiary amalgamations.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Regulatory approvals for the amalgamation schemes of subsidiaries.
Updates on income tax proceedings highlighted by auditors.
Detailed disclosures related to the amalgamation schemes in Annexure-II.
MEDIUM RISK Ongoing uncertainty regarding income tax proceedings against the company, as noted in the auditor's report.
💡 Investor Takeaway
Mankind Pharma reported standalone Profit for the period of Rs. 581.95 Crores and Revenue from operations of Rs. 3,145.22 Crores for Q2 FY27. The company's Board approved amalgamation schemes for two wholly-owned subsidiaries, effective April 01, 2027, subject to regulatory and statutory approvals.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone Profit for the period was Rs. 581.95 Crores for the quarter ended September 30, 2026.
  • Standalone Revenue from operations reached Rs. 3,145.22 Crores for the quarter ended September 30, 2026.

⚠️ Concerns

  • Auditors highlighted an emphasis of matter regarding uncertainty from income tax proceedings initiated under Section 132 of Income Tax Act, 1961.
  • Comparative standalone financial results for prior periods were restated due to business combination adjustments, affecting direct year-on-year comparisons.
📅 Company Track Record
In Q1 FY27 (July 2026 filing), Mankind Pharma's PAT increased 29.1% to INR 574 Crore, with revenue up 12.9% (as per press release). The unaudited financial results for Q1 FY27 showed a profit rise of 34.49% to Rs. 558.49 crore. The current Q2 FY27 standalone profit is Rs. 581.95 Crores.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What were Mankind Pharma's standalone profits for Q2 FY27?
Mankind Pharma reported a standalone Profit for the period of Rs. 581.95 Crores for the quarter ended September 30, 2026.
What was Mankind Pharma's standalone revenue from operations in Q2 FY27?
The standalone Revenue from operations for Mankind Pharma was Rs. 3,145.22 Crores for the quarter ended September 30, 2026.
Which subsidiaries will be amalgamated into Mankind Pharma?
Prolijune Lifesciences Private Limited and Pavi Buildwell Private Limited, both wholly-owned subsidiaries, will be amalgamated into Mankind Pharma Limited.
When is the appointed date for the amalgamation of Prolijune Lifesciences and Pavi Buildwell?
The Appointed Date for the amalgamation scheme of Prolijune Lifesciences and Pavi Buildwell with Mankind Pharma is April 01, 2027.
What financial concern was highlighted by the auditors for Mankind Pharma?
Auditors noted an emphasis of matter regarding uncertainty due to income tax proceedings initiated against the company by the Income Tax Department.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.